Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalin Mishra

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Cancers|February 26, 2020
Current Advances in the Treatment of BRAF-Mutant MelanomaHima Patel, Nour Yacoub, Rosalin Mishra, et al.
Molecular Medicine Reports|February 6, 2026
[Expression of Concern] Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin‑induced VEGF expressionGoutam Chakraborty, Shalini Jain, Smita Kale, et al.
Molecular Medicine Reports|April 12, 2011
Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expressionGoutam Chakraborty, Shalini Jain, Smita Kale, et al.
Oncotarget|July 3, 2018
Activating HER3 mutations in breast cancerRosalin Mishra, Samar Alanazi, Long Yuan, et al.
Cancers|December 23, 2022
HER3 Alterations in Cancer and Potential Clinical ImplicationsMary Kate Kilroy, SoYoung Park, Wasim Feroz, et al.
Carcinogenesis|August 4, 2025
Co-targeting KRASG12D and the HER family is efficacious in colorectal cancerMary Kate Kilroy-Gehret, Cecilia Wischmeier, SoYoung Park, et al.
Plos One|May 18, 2023
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancersSamar M Alanazi, Wasim Feroz, Rosalin Mishra, et al.
Journal of Cancer|December 28, 2018
Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in MelanomaLong Yuan, Rosalin Mishra, Hima Patel, et al.
International Journal of Molecular Sciences|September 14, 2024
Non-Muscle Myosin II A: Friend or Foe in Cancer?Wasim Feroz, Briley SoYoung Park, Meghna Siripurapu, et al.
International Journal of Molecular Sciences|March 6, 2021
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell GrowthRosalin Mishra, Long Yuan, Hima Patel, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cancers|February 26, 2020
Current Advances in the Treatment of BRAF-Mutant MelanomaHima Patel, Nour Yacoub, Rosalin Mishra, et al.
Molecular Medicine Reports|February 6, 2026
[Expression of Concern] Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin‑induced VEGF expressionGoutam Chakraborty, Shalini Jain, Smita Kale, et al.
Molecular Medicine Reports|April 12, 2011
Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expressionGoutam Chakraborty, Shalini Jain, Smita Kale, et al.
Oncotarget|July 3, 2018
Activating HER3 mutations in breast cancerRosalin Mishra, Samar Alanazi, Long Yuan, et al.
Cancers|December 23, 2022
HER3 Alterations in Cancer and Potential Clinical ImplicationsMary Kate Kilroy, SoYoung Park, Wasim Feroz, et al.
Carcinogenesis|August 4, 2025
Co-targeting KRASG12D and the HER family is efficacious in colorectal cancerMary Kate Kilroy-Gehret, Cecilia Wischmeier, SoYoung Park, et al.
Plos One|May 18, 2023
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancersSamar M Alanazi, Wasim Feroz, Rosalin Mishra, et al.
Journal of Cancer|December 28, 2018
Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in MelanomaLong Yuan, Rosalin Mishra, Hima Patel, et al.
International Journal of Molecular Sciences|September 14, 2024
Non-Muscle Myosin II A: Friend or Foe in Cancer?Wasim Feroz, Briley SoYoung Park, Meghna Siripurapu, et al.
International Journal of Molecular Sciences|March 6, 2021
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell GrowthRosalin Mishra, Long Yuan, Hima Patel, et al.
Pageof 3